Skip to content
Homepage
Author:
ZENTALIS PHARMACEUTICALS
Posted Date:
August 17, 2026
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
ZENTALIS PHARMACEUTICALS
August 17, 2026
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
ZENTALIS PHARMACEUTICALS
August 13, 2026
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
ZENTALIS PHARMACEUTICALS
August 13, 2026
Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates
ZENTALIS PHARMACEUTICALS
August 6, 2026
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZENTALIS PHARMACEUTICALS
August 3, 2026
